Drug Profile
Interferon beta-1b biosimilar - Axxo
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator AXXO
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Multiple sclerosis
Most Recent Events
- 17 Sep 2013 Investigation for Multiple sclerosis in Germany (Parenteral)